Fig. 2: Inhibition of intraosseous lymphatic proliferation alone is sufficient to increase osteoclast activity and bone destruction.

a Micro-CT images depicting cranial bone resorption from both superior and inferior perspectives after continuous treatment with SAR131675 for 14 days. b, TRAP staining in mouse cranial bones after SAR131675 treatment. Scale bars: 100 μm. c H&E staining in mouse cranial bones after SAR131675 treatment. Scale bars: 100 μm. d Representative IF images for LYVE1 (green) and PROX1 (red) expressions in cranial bones on day 14 after SAR131675 treatments. e Quantification of the lytic area in calvarial bone tissues analyzed by micro-CT (n = 5). f Quantification of TRAP-stained areas in calvarial bone sections (n = 5). g Quantification of inflammatory infiltrating cells in calvarial bone sections (n = 5). h, i The corresponding quantification data for LYVE1 and PROX1 expressions in cranial bones on day 14 after SAR131675 treatments (n = 5). Data are shown as means ± SD. P values were calculated by the two-tailed Student’s t-test.